Professor Andreas Busch, PhD

Member of Scientific Advisory Board

Andreas is a member of Arix’s Scientific Advisory Board. He has extensive R&D and portfolio leadership experience across a broad range of therapeutic categories, including significant expertise in rare and orphan diseases. He is currently Chief Innovation Officer at Cylerion Therapeutic, where he is primarily focused on delivering the greatest possible patient impact and shareholder value creation from Cyclerion’s current pipeline of five sGC stimulator programs. Prior to which he served as Head of Research and Development and Chief Scientific Officer at Shire and as Head of Drug Discovery and a member of the Executive Committee at Bayer Pharma. Prior to that, Andreas was Global Head of Cardiovascular Research at Hoechst and Sanofi-Aventis.

Andreas has been a member of several Supervisory and Scientific Boards, including the German Cancer Research Center, the University of Tübingen, the Max-Delbrück-Center and the Max-Planck-Institute of Molecular Genetics. He also holds the title of Extraordinary Professor of Pharmacology at the Johann Wolfgang Goethe-University in Frankfurt, Germany. He is the author of some 400 publications and abstracts, and received the prestigious Sir Bernard Katz and Franz Volhard Awards for his work on renal and cardiac ion channels and transporters.

He received his PhD in Pharmacology from the Johann Wolfgang Goethe-University Frankfurt.